The market capitalisation (m-cap) of Sun Pharmaceutical Industries (Sun Pharma) surpassed the Rs 3-lakh-crore mark on December 18 afternoon deals as investors flocked to defensive plays in an otherwise subdued market.
The stock of this pharma giant gained 2.5 percent to hit a 52-week high of Rs 1,267 per share on December 18. So far this year, Sun Pharma shares surged over 26 percent as against a 17 percent rise in the benchmark Sensex.
So far on December 18, around 1.5 million equity shares changed hands in both BSE and NSE as against a one-month average of 1.9 million equity shares.
Follow live blog for all the market action
On December 18, Sun Pharma was the top gainer in the Nifty Pharma index. Zydus Life, Torrent Pharma, and Lupin too were in the league.
Earlier, on December 13, Sun Pharma's specialty product 'Ilumetri' was included in category-B of China's national reimbursement drug list, which shall be officially implemented from January 1, 2024.
'Ilumetri' is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Also read: Sun Pharma, Lupin recall drugs in US market: USFDA
That apart, Sun Pharma delivered a letter to Taro Pharmaceutical Industries that contained a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares held by the company or its affiliates, for a purchase price of $43 per share, in cash from an earlier price of $38 per share.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
